SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Illustration of the US Capitol building surrounded by stacks of paper
Opinion
Ruling in REGENXBIO-Sarepta Patent Case Threatens Gene Therapy Market
The recent invalidation of an AAV gene therapy patent overlooks the complexity of innovation in biotechnology and could put a broad swath of intellectual property at risk.
August 20, 2024
 · 
5 min read
 · 
Richard B. Emmons
A Walgreens' retail location in Indiana
Decentralized trials
Walgreens, BARDA Team in $100M Partnership to Boost Decentralized Clinical Trials
The retail pharmacy giant and the Biomedical Advanced Research and Development Authority hope to make decentralized clinical trials more accessible and representative of the U.S. population.
August 20, 2024
 · 
2 min read
 · 
Tristan Manalac
AbbVie's office in South San Francisco, California
Approvals
AbbVie, Genmab Secure European Label Expansion for Tepkinly in Follicular Lymphoma
Two months after winning FDA approval in the same indication, AbbVie and Genmab on Monday secured the European Commission’s nod for its bispecific antibody Tepkinly for the most common type of low-grade non-Hodgkin lymphoma.
August 20, 2024
 · 
2 min read
 · 
Tristan Manalac
Eli Lilly's biotechnology center in California
Diabetes
Lilly’s Tirzepatide Cuts Type 2 Diabetes Risk by 94% in Overweight, Obese Adults
Eli Lilly released topline Phase III data on Tuesday showing that after more than three years of follow-up, pre-diabetic patients treated with tirzepatide were less likely to progress to type 2 diabetes.
August 20, 2024
 · 
2 min read
 · 
Tristan Manalac
Entrance to the U.S. Department of Health and Human Services in Washington, DC
Drug pricing
More Than Half of IRA Negotiation Savings to Come From Three Drugs: Report
Amgen’s Enbrel, Bristol Myers Squibb’s Eliquis and Johnson & Johnson’s Stelara will account for 51.4% of the Inflation Reduction Act’s drug price negotiation savings in 2026, according to the Brookings Institution.
August 20, 2024
 · 
2 min read
 · 
Tristan Manalac
Sign outside BioNTech's building in Germany
FDA
FDA Lifts Partial Hold on BioNTech, MediLink’s ADC Cancer Trial
In June, the regulator placed a partial clinical hold on a Phase I trial of the companies’ antibody-drug conjugate after three patient deaths were reported.
August 19, 2024
 · 
2 min read
 · 
Tyler Patchen
FDA signage at its headquarters in Maryland
Regulatory
Liquidia Misses Full Approval for Pulmonary Hypertension Drug as Competitor Retains Market Exclusivity
The FDA on Monday only granted Liquidia’s Yutrepia tentative approval, keeping it off the U.S. market until after rival United Therapeutics’ exclusivity expires in May 2025.
August 19, 2024
 · 
2 min read
 · 
Tristan Manalac
Bavarian Nordic's sign outside its facility in Germany
Infectious disease
Bavarian Nordic Accelerates Mpox Vaccine Production to Respond to Global Emergency
The Danish company on Saturday announced plans to increase production of its vaccine Jynneos on the heels of the World Health Organization last week declaring mpox a global health emergency.
August 19, 2024
 · 
2 min read
 · 
Tristan Manalac
A child's hands with blisters and painful rashes
Infectious disease
Mid-Stage Study Finds Only Mpox Drug Ineffective Against Current Outbreak
SIGA Technologies’ TPOXX did not outperform placebo at resolving lesions in patients with clade I mpox, the new strain that has spread through parts of Africa and is reaching beyond the continent.
August 19, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS